Thorac Cardiovasc Surg 2007; 55(1): 44-47
DOI: 10.1055/s-2006-924441
Original Thoracic

© Georg Thieme Verlag KG Stuttgart · New York

Survival Following Complete Resection of Multifocal T4 Node-Negative NSCLC: A Retrospective Study

A. Terzi1 , 3 , G. Falezza1 , 3 , C. Benato1 , G. Genestreti2 , 3 , A. Santo2 , 3 , S. Furia1 , B. Feil1 , F. Calabrò1 , 3
  • 1Thoracic Surgery Unit, Verona City Hospital, Verona, Italy
  • 2Clinical Oncology, University of Verona, Verona, Italy
  • 3Gruppo Interdisciplinare Veronese Oncologia Polmonare (GIVOP), Azienda Ospedaliera-Universitaria di Verona, Verona, Italy
Further Information

Publication History

received April 18, 2006

Publication Date:
06 February 2007 (online)

Abstract

Background: Multifocal NSCLC in the same lobe are staged as T4. This study was designed to assess the impact of multifocal NSCLC in the same lobe on survival in completely resected node-negative patients to determine whether the T4 (stage III B) designation is valid.

Method: We reviewed our database from October 1987 through 2004 to identify completely resected patients with N0 multifocal (T4) NSCLC. Patients with multifocal pure bronchiolo-alveolar carcinoma were excluded. Thirty-two patients had multifocal NSCLC in the same lobe and were node-negative.

Results: Five-year survival rate was 42.4 % for the whole group with a median survival of 48 months. When tumors were staged independently of the satellite nodule/s, patients in stage I A had a 5-year survival rate of 55 % while those in stage I B had a rate of 22 %.

Conclusion: Patients with N0 multifocal intralobar NSCLC should be upstaged but not to stage IIIB. They should undergo complete surgical resection whenever multiple nodules are detected preoperatively.

References

  • 1 Mountain C F. Revision in the international system for staging lung cancer.  Chest. 1997;  111 1710-1717
  • 2 UICC .TNM Supplement 1993: A Commentary on Uniform Use. Berlin, Germany; Springer Verlag 1993: 34-36
  • 3 Detterbeck F C, Jones D R, Funkhouser Jr W K. Satellite nodules and multiple primary cancers. Detterbeck FC, Rivera MP, Socinski MA, Rosemann JG Diagnosis and Treatment of Lung Cancer. An Evidence-Based Guide for the Practicing Clinician. Philadelphia, PA; WB Saunders 2001: 437-449
  • 4 Travis W D, Colby T V, Corrin B. et al .Histologic typing of lung and pleural tumors. World Health Organization Pathology Panel World Health Organization International Histologic Classification of Tumors. Berlin; Springer Verlag 1999: 5
  • 5 Henson D A, Gloeckler Ries L A. On estimation of survival.  Semin Surg Oncol. 1994;  10 2-6
  • 6 Warren W H, Faber L P. Extended resection for locally advanced non small cell lung cancer. Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD Lung Cancer Principles and Practice. Philadelphia, PA; Lippincott, Williams, and Wilkins 2000: 694-715
  • 7 Urschel J D, Urschel D M, Anderson T M, Antkowiak J A, Takita H. Prognostic implications of pulmonary satellite nodules: are the 1997 staging revisions appropriate?.  Lung Cancer. 1998;  21 83-87
  • 8 Battafarano R J, Meyers B F, Guthrie T J, Cooper J D, Patterson G A. Surgical resection of multifocal non-small cell lung cancer is associated with prolonged survival.  Ann Thorac Surg. 2002;  74 988-993
  • 9 Deslauriers J, Brisson J, Cartier R. et al . Carcinoma of the lung. Evaluation of satellite nodules as a factor-influencing prognosis after resection.  J Thorac Cardiovasc Surg. 1989;  97 505-512
  • 10 Mountain C F. A new international staging system for lung cancer.  Chest. 1986;  89 (Suppl 4) 225s-233s
  • 11 Carbone E, Asamura H, Takei H. et al . T2 tumors larger than five centimetres in diameter can be upgraded to T3 in non-small cell lung cancer.  J Thorac Cardiovasc Surg. 2001;  122 907-912
  • 12 Cangir A K, Kutlay H, Akal M, Gungor A, Ozdemir N, Akay H. Prognostic value of tumor size in non-small cell lung cancer larger than five centimetres in diameter.  Lung Cancer. 2004;  46 325-331
  • 13 Watanabe Y, Shimizu J, Ota M. et al . Proposal regarding some deficiencies in the new international staging system for non-small cell lung cancer.  Jpn J Clin Oncol. 1991;  21 160-168
  • 14 Okada M, Tsubota N, Yoshimura M, Miyamoto Y, Nakai R. Evaluation of TNM classification for lung carcinoma with ipsilateral intrapulmonary metastasis.  Ann Thorac Surg. 1999;  68 326-330
  • 15 Slaughter D P, Southwick H W, Smejkal W. “Field cancerization” in oral stratified squamous epithelium: clinical implications of multicentric origin.  Cancer. 1953;  6 963
  • 16 Johnson B E. Second lung cancer in patients after treatment for an initial lung cancer.  J Natl Cancer Inst. 1998;  90 1335
  • 17 Rosengart T K, Martini N, Ghossi P, Burt M. Multiple primary carcinomas: prognosis and treatment.  Ann Thorac Surg. 1991;  89 378-385
  • 18 Ichinose Y, Hara N, Ohta M. Synchronous lung cancer defined by deoxyribonucleic acid flow cytometry.  J Thorac Cardiovasc Surg. 1991;  102 418-424
  • 19 Kandioler D, Dekan G, End. et al . A molecular genetic differentiation between primary lung cancers and lung metastases of other tumors.  J Thorac Cardiovasc Surg. 1996;  111 827-832
  • 20 Matsuzoe D, Hideshima T, Ohshima K, Kawahara K, Shirakusa T, Kimura A. Discrimination of double primary lung cancer from intrapulmonary metastasis by p 53 gene mutation.  Br J Cancer. 1999;  79 1549-1552

MD Alberto Terzi

U. O. di Chirurgia Toracica
Azienda Ospedaliera-Universitaria Verona

P. le Stefani 1

37126 Verona

Italy

Phone: + 39 04 58 07 23 12

Fax: + 39 04 58 07 20 46

Email: alterzi@libero.it

    >